A report of an AstraZeneca Bristol Myers Squibb merger rattled London’s benchmark on Monday, wiping more than £17 billion off AstraZeneca’s market value and capping the FTSE 100’s advance even as European peers surged on easing geopolitical tensions.
AstraZeneca fell around 5%, trimming significant points from the index, which traded flat by mid-morning. Brent crude dropped 4.7% and WTI lost 5.8% after Donald Trump confirmed peace talks with Iran would resume, having called off military strikes that had rattled markets into Friday’s close.
Merger Report Sends AstraZeneca Shares Lower
The Financial Times reported over the weekend that an AstraZeneca Bristol Myers Squibb merger had been under discussion for several months. Reuters, citing a person familiar with the matter, corroborated that talks had taken place, though FT sources told the paper a deal may never materialise. Neither company returned requests for comment.
The denial came swiftly. Quartz reported that a senior source close to the matter subsequently said there is ‘no deal’ and there ‘never was a deal to be done’, directly contradicting the earlier reports.
The proposed tie-up would have created a combined company valued at approximately $400 billion, based on AstraZeneca’s market capitalisation of around $264 billion and Bristol Myers Squibb’s $133 billion as of Friday, according to CNBC. The Guardian reported that AstraZeneca has separately committed to investing $50 billion in US research and manufacturing by 2030, and completed a direct listing on the New York Stock Exchange in June.
‘The FTSE 100’s advance was constrained by a negative reaction to AstraZeneca’s reported interest in a merger with Bristol Myers Squibb and by weakness in its oil and gas heavyweights BP and Shell,’ said Russ Mould, investment director at AJ Bell. ‘However, aviation-linked stocks and housebuilders made solid progress in London. Other European markets chalked up material gains and futures pointed towards a positive showing on Wall Street later.’
Antitrust Overlap and Patent Cliff Add Complexity
The two companies’ oncology businesses overlap heavily. AstraZeneca’s oncology franchise generated around $25 billion in 2025 sales, close to half of its total revenue. Bristol Myers Squibb derived more than 40% of its overall sales from oncology drugs in the first six months of 2026, according to Reuters. Antitrust lawyers have said the overlap would draw scrutiny from the Federal Trade Commission and require meaningful divestitures.
Bristol Myers Squibb faces a patent cliff on its cancer immunotherapy Opdivo and blood thinner Eliquis, both of which could face generic competition by 2028, according to Yahoo Finance. The company raised its full-year 2026 revenue forecast last week, driven by Eliquis and newer drugs including heart treatment Camzyos and anaemia drug Reblozyl. Bristol Myers Squibb reported Q2 2026 earnings per share of $2.04, beating the consensus estimate of $1.61, on revenue of $12.97 billion against estimates of $11.71 billion.
AstraZeneca’s share price has more than quadrupled during chief executive Pascal Soriot’s 14-year tenure, outperforming both the wider FTSE 100 and rival GSK, Reuters reported. The merger report arrives roughly 12 years after AstraZeneca fended off a takeover approach from Pfizer.
Oil Drop Lifts Housebuilders, Weighs on Energy Stocks
Away from AstraZeneca, the Trump-Iran diplomacy drove sharp moves across the index. Persimmon rose 3.7%, topping the FTSE 100 leaderboard, as lower oil prices and reduced expectations for near-term interest rate cuts lifted housebuilders. Aviation-linked stocks also advanced.
Energy heavyweights BP and Shell fell alongside the crude price. Tobacco stocks were among the worst performers, reflecting a broader risk-on tone that rotated capital away from defensive sectors.
Daniela Hathorn, analyst at Capital.com, said US futures were pointing to a positive open, with the weekend delivering ‘the de-escalation traders had been hoping for’ after Gulf allies including Saudi Arabia pushed for diplomacy over confrontation.
Whether the AstraZeneca Bristol Myers Squibb merger speculation resurfaces will depend partly on how antitrust regulators respond to deal activity in oncology: any formal approach would face close FTC scrutiny given the companies’ competing cancer immunotherapy portfolios.
